2006
DOI: 10.1016/j.euroneuro.2006.01.007
|View full text |Cite
|
Sign up to set email alerts
|

Proteomic analysis of rat hippocampus and frontal cortex after chronic treatment with fluoxetine or putative novel antidepressants: CRF1 and NK1 receptor antagonists

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

5
42
1
1

Year Published

2007
2007
2015
2015

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 55 publications
(49 citation statements)
references
References 62 publications
5
42
1
1
Order By: Relevance
“…Actin has previously been identified in proteomic studies following antidepressant administration, whereby chronic treatment with the SSRI fluoxetine led to a decrease in actin levels in the hippocampus (Carboni et al, 2006), a similar result to that seen four weeks after chronic ECS administration in our study. As suggested by Carboni et al (2006), it is possible that modifications in actin isoform levels are involved in antidepressant-induced plasticity (Carboni et al, 2006;Guest et al, 2004). The role of the actin cytoskeleton in antidepressant action, even four weeks after ECS administration, implies an important role for this protein in the persisting effects of ECS.…”
Section: Discussionsupporting
confidence: 89%
“…Actin has previously been identified in proteomic studies following antidepressant administration, whereby chronic treatment with the SSRI fluoxetine led to a decrease in actin levels in the hippocampus (Carboni et al, 2006), a similar result to that seen four weeks after chronic ECS administration in our study. As suggested by Carboni et al (2006), it is possible that modifications in actin isoform levels are involved in antidepressant-induced plasticity (Carboni et al, 2006;Guest et al, 2004). The role of the actin cytoskeleton in antidepressant action, even four weeks after ECS administration, implies an important role for this protein in the persisting effects of ECS.…”
Section: Discussionsupporting
confidence: 89%
“…To our knowledge, this is the first time 14-3-3 protein status in MD is studied. The unaltered levels suggest no role for these proteins in MD and no modulation of protein levels by antidepressant treatment despite the modulation by antidepressants suggested in cellular and in animal models (Carboni et al, 2006;Cecconi et al, 2007;Malki et al, 2012).…”
mentioning
confidence: 76%
“…To date, there is no reported data about 14-3-3 proteins in major depressive disorder (MD), though modulation of 14-3-3β and 14-3-3ζ isoforms has been described in cellular and in animal models after chronic antidepressant treatment (Carboni et al, 2006;Cecconi et al, 2007;Malki et al, 2012). 14-3-3 protein activates tyrosine hydroxylase, the rate-limiting enzyme in the biosynthesis of noradrenaline (Ichimura et al, 1987).…”
Section: Introductionmentioning
confidence: 98%
“…We identified many regulated protein spots that in other studies were already reported to be associated with schizophrenia. These include ATP-synthase-b subunit, 63,77 a-internexin, 63,77 phosphatidylethanolamine-binding protein 58 and prohibitin. 58 Noteworthy, many of the proteins found in the latter study by Clark et al 58 to be regulated in the anterior cingulate cortex in schizophrenia were also identified in our study of the DPLFC.…”
Section: Discussionmentioning
confidence: 99%